RA Capital fund trims Vor Biopharma (NASDAQ: VOR) stake with 165,150-share sale

Rhea-AI Filing Summary

Vor Biopharma Inc. reported an open‑market sale of its common stock by entities associated with RA Capital. On April 22, 2026, RA Capital Healthcare Fund LP sold 165,150 shares of Vor Biopharma common stock at a weighted average price of $15.77, through multiple trades between $15.75 and $15.85. After these transactions, the fund continued to hold 2,402,095 shares indirectly reported. RA Capital Management, L.P., its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests.

Insider Trade Summary

Net Seller: 165,150 shares ($2,604,416)

Net Sell 1 txn

Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.

Role null | null | null | null

Sold 165,150 shs ($2.60M)

Type	Security	Shares	Price	Value
Sale	Common Stock	165,150	$15.77	$2.60M

Holdings After Transaction: Common Stock — 2,402,095 shares (Indirect, See footnotes)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund.

Key Figures

Shares sold: 165,150 shares Weighted average sale price: $15.77 per share Price range of trades: $15.75–$15.85 per share +1 more

4 metrics

Shares sold 165,150 shares Open-market sale on April 22, 2026

Weighted average sale price $15.77 per share Price across multiple trades in the April 22, 2026 sale

Price range of trades $15.75–$15.85 per share Range for multiple transactions included in the reported sale

Shares held after transaction 2,402,095 shares Indirect holdings reported for RA Capital Healthcare Fund LP after sale

Key Terms

weighted average price, disclaims beneficial ownership, pecuniary interest, indirect ownership

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

disclaims beneficial ownership regulatory

"Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities"

pecuniary interest financial

"except to the extent of its or his respective pecuniary interest therein."

indirect ownership regulatory

"ownership_type": "indirect""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/22/2026		S		165,150	D	$15.77(1)	2,402,095	I	See footnotes(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

3. Held directly by the Fund.

Remarks:

Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	04/24/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	04/24/2026
	/s/ Peter Kolchinsky, individually	04/24/2026
	/s/ Rajeev Shah, individually	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Vor Biopharma (VOR) disclose in this Form 4?

Vor Biopharma disclosed that RA Capital Healthcare Fund LP executed an open‑market sale of 165,150 shares of common stock on April 22, 2026. The transaction was reported as an indirect sale by entities associated with RA Capital Management, L.P., which remain significant shareholders.

How many Vor Biopharma (VOR) shares were sold and at what price range?

The filing shows a sale of 165,150 Vor Biopharma common shares at a weighted average price of $15.77. Footnotes explain the shares were sold in multiple transactions, with prices ranging from $15.75 to $15.85 inclusive across those trades.

How many Vor Biopharma (VOR) shares does the RA Capital fund hold after the sale?

After the reported sale, RA Capital Healthcare Fund LP holds 2,402,095 shares of Vor Biopharma common stock. These holdings are reported as indirect, with RA Capital entities and principals disclaiming beneficial ownership except to the extent of their respective pecuniary interests.

Who is RA Capital Management in relation to Vor Biopharma (VOR)?

RA Capital Management, L.P. is the investment manager for RA Capital Healthcare Fund LP, which holds Vor Biopharma shares. Its general partner is RA Capital Management GP, LLC, whose managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah are also reporting persons on this Form 4.

What does the beneficial ownership disclaimer mean in this Vor Biopharma (VOR) filing?

The filing states that RA Capital Management, RA Capital Management GP, RA Capital Healthcare Fund, Dr. Kolchinsky, and Mr. Shah each disclaim beneficial ownership of the reported securities, except for their respective pecuniary interests. This limits how much personal economic ownership they attribute to themselves for regulatory reporting.

Was the Vor Biopharma (VOR) insider sale a single trade or multiple trades?

The Form 4 explains that the reported price is a weighted average, indicating multiple trades occurred. Shares were sold in several transactions within a price range of $15.75 to $15.85, and the reporting persons can provide detailed trade‑by‑trade information upon request.